Recursion, a clinical-stage biotechnology company decoding biology to by industrializing drug discovery, development and beyond through disruptive innovation, expanded its existing strategic collaboration in fibrosis with Bayer AG. This will now include Recursion’s inferential search capabilities based on its growing maps of human cellular biology, giving Bayer the ability to further accelerate the work already underway in expanding novel fibrotic hypotheses. Recursion and Bayer may now wo...